MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children

Pediatric Nephrology

Volumn 22, Issue 1, 2007, Pages 44-51

  Wasilewska, Anna ^a   Zalewski, Grzegorz ^a   Chyczewski, Lech ^a   Zoch Zwierz, Walentyna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Children; Glucocorticoids; MDR 1 polymorphisms; Nephrotic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYSTEINE; GLYCINE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; STEROID; THREONINE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADOLESCENT; ADULT; ALLELES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC MARKERS; GLUCOCORTICOIDS; HAPLOTYPES; HUMANS; MALE; MUTATION; NEPHROTIC SYNDROME; P-GLYCOPROTEIN; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE;

EID: 33846441202     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0275-3     Document Type: Article

References (36)

1. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242-1249
2. Ahmad H, Tejani A (2000) Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 84:342-346
3. Lande MB, Gullion C, Hogg RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S 3rd, Strife CF, Arbus G (2003) Long versus standard initial steroid therapy for children with the nephrotic syndrome. A report from the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 18:342-634
4. Sakaeda, T, Nakamura T, Okumura K (2004) Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 4:1385-1398
5. Dilger K, Schwab M, Fromm MF (2004) Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10:578-583
6. Farrell RJ, Menconi MJ, Keates AC, Kelly CP (2002) P-glycoprotein-170 inhibition significantly reduces cortisol and cyclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol Ther 16:1021-1031
7. Klimecki WT, Futscher BW, Grogan TM, Dalton WS (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-2458
8. Stachowski J, Zanker CB, Runowski D, Zaniew M, Peszko A, Medynska A, Zwolinska D, Rogowska-Kalisz A, Hyla-Klekot L, Szprygner K, Weglarska J, Sieniawska M, Musial W, Maciejewski J, Baldamus CA (2000) Resistance to therapy in primary nephrotic syndrome: Effect of MDR1 gene activity. Pol Merkuriusz Lek 8:218-221
9. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L (2004) P-glycoprotein in autoimmune diseases. Autoimmun Rev 3:188-192
10. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, Tanaka Y (2004) Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9:1265-1273
11. Raghu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258-1264
12. Gollapud S, Gupta S (2001) Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: A possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 21:420-340
13. Ieiri I, Takane H, Otsubo K (2004) The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 43:553-576
14. Woodahl EL, Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11-19
15. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM, Goldstein DB (2004) Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 14:1333-1344
16. Kabuki N, Okugawa T, Hayakawa H, Tomizawa S, Kasahara T, Uchiyama M (1998) Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 12:467-470
17. Constantinescu AR, Shah HB, Foote EF, Weiss LS (2000) Predicting first-year relapses in children with nephrotic syndrome. Pediatrics 105:492-495
18. Takeda A, Takimoto H, Mizusawa Y, Simoda M (2001) Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 16:888-893
19. Nasi M. Aedelmann CM, Berstein J, Barnett HL (1992) The nephrotic syndrome. In: Edelmann CM, Berstein J, Meadow SR, Spitzer A, Travis LB (eds) Pediatric kidney disease, vol 2. Little, Brown and Company, Boston, pp 1247-1266
20. International Study of Kidney Disease in Children (1982) Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 101:514-518
21. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie (1987) Cyclophosphamide treatment of steroid dependent nephrotic syndrome: Comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fär Pädiatrische Nephrologie. Arch Dis Child 62:1102-1106
22. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174
23. Imani S, Jusko WJ, Steiner R (1999) Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. Pediatr Transplant 3:126-130
24. Rostin M, Barthe P, Houin G, Alvinerie M, Bouissou F (1990) Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Pediatr Nephrol 4:470-473
25. Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A (1984) Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol 17:423-431
26. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay AB (1991) Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 144:1016-1025
27. Magee MH, Blum RA, Lates CD, Jusko WJ (2002) Pharmacokinetic/ pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol 53:474-484
28. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y (2005) Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 52:1676-1683
29. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ (2002) The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63:765-770
30. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N, Nishino H, Tanaka T, Hirota Y, Kubo T (2003) ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13:675-682
31. Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: Fact or fiction? Drug Metab Pharmacokinet 20:391-414
32. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E (2006) MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 79: 325-338
33. Kurzawski M, Pawlik A, Gornik W, Drozdzik M (2006) Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 58:35-40
34. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199
35. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG (2003) Pharmacogenetics of Membrane Transporters Investigators. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494
36. Morita N, Yasumori T, Nakayama K (2003) Human MDR1 polymorphism: G2677T/ A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65:1843-1852